[1]
Vasileiou E, Apsemidou A, Vyzantiadis TA, Tragiannidis A. Invasive candidiasis and candidemia in pediatric and neonatal patients: A review of current guidelines. Current medical mycology. 2018 Sep:4(3):28-33. doi: 10.18502/cmm.4.3.173. Epub
[PubMed PMID: 30619967]
[2]
Jansook P, Fülöp Z, Ritthidej GC. Amphotericin B loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): physicochemical and solid-solution state characterizations. Drug development and industrial pharmacy. 2019 Apr:45(4):560-567. doi: 10.1080/03639045.2019.1569023. Epub 2019 Jan 25
[PubMed PMID: 30632399]
[3]
Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, Krobot KJ, Gerth WC, Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006 Aug 15:43(4):e29-38
[PubMed PMID: 16838223]
[4]
Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013 Jun:73(9):919-34. doi: 10.1007/s40265-013-0069-4. Epub
[PubMed PMID: 23729001]
Level 2 (mid-level) evidence
[5]
Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Nov 15:45(10):1255-65
[PubMed PMID: 17968818]
Level 1 (high-level) evidence
[6]
Maertens J, Pagano L, Azoulay E, Warris A. Liposomal amphotericin B-the present. The Journal of antimicrobial chemotherapy. 2022 Nov 25:77(Suppl_2):ii11-ii20. doi: 10.1093/jac/dkac352. Epub
[PubMed PMID: 36426672]
[7]
Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Aug 15:63(4):433-42. doi: 10.1093/cid/ciw444. Epub
[PubMed PMID: 27481947]
Level 1 (high-level) evidence
[8]
Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, Carvalho EM, Ephros M, Jeronimo S, Magill A. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Dec 15:63(12):e202-e264
[PubMed PMID: 27941151]
Level 1 (high-level) evidence
[9]
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Feb 15:62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16
[PubMed PMID: 26679628]
Level 1 (high-level) evidence
[10]
Shikanai-Yasuda MA, Mendes RP, Colombo AL, Queiroz-Telles F, Kono ASG, Paniago AMM, Nathan A, Valle ACFD, Bagagli E, Benard G, Ferreira MS, Teixeira MM, Silva-Vergara ML, Pereira RM, Cavalcante RS, Hahn R, Durlacher RR, Khoury Z, Camargo ZP, Moretti ML, Martinez R. Brazilian guidelines for the clinical management of paracoccidioidomycosis. Revista da Sociedade Brasileira de Medicina Tropical. 2017 Sep-Oct:50(5):715-740. doi: 10.1590/0037-8682-0230-2017. Epub 2017 Jul 12
[PubMed PMID: 28746570]
[11]
Cavassin FB, Baú-Carneiro JL, Vilas-Boas RR, Queiroz-Telles F. Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections. Infectious diseases and therapy. 2021 Mar:10(1):115-147. doi: 10.1007/s40121-020-00382-7. Epub 2021 Feb 1
[PubMed PMID: 33523419]
Level 3 (low-level) evidence
[12]
Pruthi HS. When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection. Current clinical microbiology reports. 2022:9(4):60-68. doi: 10.1007/s40588-022-00184-0. Epub 2022 Nov 3
[PubMed PMID: 36345368]
[13]
Al Balushi A, Khamis F, Klaassen CHW, Gangneux JP, Van Hellemond JJ, Petersen E. Double Infection With Leishmania tropica and L. major in an HIV Patient Controlled With High Doses of Amphotericin B. Open forum infectious diseases. 2018 Dec:5(12):ofy323. doi: 10.1093/ofid/ofy323. Epub 2018 Dec 7
[PubMed PMID: 30619911]
[14]
Rybak JM, Fortwendel JR, Rogers PD. Emerging threat of triazole-resistant Aspergillus fumigatus. The Journal of antimicrobial chemotherapy. 2019 Apr 1:74(4):835-842. doi: 10.1093/jac/dky517. Epub
[PubMed PMID: 30561652]
[15]
Groll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 May 2:68(Suppl 4):S260-S274. doi: 10.1093/cid/ciz076. Epub
[PubMed PMID: 31222253]
[16]
Adler-Moore J, Lewis RE, Brüggemann RJM, Rijnders BJA, Groll AH, Walsh TJ. Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 May 2:68(Suppl 4):S244-S259. doi: 10.1093/cid/ciz064. Epub
[PubMed PMID: 31222254]
[17]
Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrobial agents and chemotherapy. 2002 Mar:46(3):828-33
[PubMed PMID: 11850268]
[18]
Lestrade PPA, Meis JF, Melchers WJG, Verweij PE. Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2019 Jul:25(7):799-806. doi: 10.1016/j.cmi.2018.11.027. Epub 2018 Dec 21
[PubMed PMID: 30580035]
[19]
Sun HY, Alexander BD, Lortholary O, Dromer F, Forrest GN, Lyon GM, Somani J, Gupta KL, del Busto R, Pruett TL, Sifri CD, Limaye AP, John GT, Klintmalm GB, Pursell K, Stosor V, Morris MI, Dowdy LA, Munoz P, Kalil AC, Garcia-Diaz J, Orloff S, House AA, Houston S, Wray D, Huprikar S, Johnson LB, Humar A, Razonable RR, Husain S, Singh N. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Dec 1:49(11):1721-8. doi: 10.1086/647948. Epub
[PubMed PMID: 19886800]
[20]
Smith C, Lee SC. Current treatments against mucormycosis and future directions. PLoS pathogens. 2022 Oct:18(10):e1010858. doi: 10.1371/journal.ppat.1010858. Epub 2022 Oct 13
[PubMed PMID: 36227854]
Level 3 (low-level) evidence
[21]
O'Grady N, McManus D, Briggs N, Azar MM, Topal J, Davis MW. Dosing implications for liposomal amphotericin B in pregnancy. Pharmacotherapy. 2023 May:43(5):452-462. doi: 10.1002/phar.2784. Epub 2023 Mar 16
[PubMed PMID: 36862037]
[23]
Pandey K, Pal B, Siddiqui NA, Rabi Das VN, Murti K, Lal CS, Verma N, Babu R, Ali V, Kumar R, Das P. Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India. The American journal of tropical medicine and hygiene. 2017 Nov:97(5):1498-1502. doi: 10.4269/ajtmh.17-0094. Epub 2017 Oct 10
[PubMed PMID: 29016288]
[24]
Usami E, Kimura M, Kanematsu T, Yoshida S, Mori T, Nakashima K, Matsuoka T, Yoshimura T, Mori H, Sugiyama T, Teramachi H. Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B. Experimental and therapeutic medicine. 2014 Apr:7(4):941-946
[PubMed PMID: 24669255]
[25]
Botero Aguirre JP, Restrepo Hamid AM. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. The Cochrane database of systematic reviews. 2015 Nov 23:2015(11):CD010481. doi: 10.1002/14651858.CD010481.pub2. Epub 2015 Nov 23
[PubMed PMID: 26595825]
Level 1 (high-level) evidence
[26]
Vaish E, Gupta KK, Ansari SA, Singh KK. Amphotericin B induced pancytopenia. Journal of family medicine and primary care. 2022 Sep:11(9):5692-5695. doi: 10.4103/jfmpc.jfmpc_321_22. Epub 2022 Oct 14
[PubMed PMID: 36505588]
[27]
Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Revista iberoamericana de micologia. 2009 Dec 31:26(4):223-7. doi: 10.1016/j.riam.2009.06.003. Epub
[PubMed PMID: 19836985]
[28]
Trejtnar F, Mandíková J, Kočíncová J, Volková M. Renal handling of amphotericin B and amphotericin B-deoxycholate and potential renal drug-drug interactions with selected antivirals. Antimicrobial agents and chemotherapy. 2014 Oct:58(10):5650-7. doi: 10.1128/AAC.02829-14. Epub 2014 Jun 23
[PubMed PMID: 24957831]
[29]
Dobrek L. A Synopsis of Current Theories on Drug-Induced Nephrotoxicity. Life (Basel, Switzerland). 2023 Jan 24:13(2):. doi: 10.3390/life13020325. Epub 2023 Jan 24
[PubMed PMID: 36836682]
[30]
Collazos J, Martínez E, Mayo J, Ibarra S. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2001 Oct 1:33(7):E75-82
[PubMed PMID: 11528589]
Level 3 (low-level) evidence
[31]
Bohm NM, Hoover KC, Wahlquist AE, Zhu Y, Velez JC. Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B. Antimicrobial agents and chemotherapy. 2015 Nov:59(11):6816-23. doi: 10.1128/AAC.01306-15. Epub 2015 Aug 17
[PubMed PMID: 26282423]
Level 2 (mid-level) evidence
[32]
Nath P, Basher A, Harada M, Sarkar S, Selim S, Maude RJ, Noiri E, Faiz A. Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion. Tropical doctor. 2014 Oct:44(4):241-2. doi: 10.1177/0049475514543655. Epub 2014 Aug 19
[PubMed PMID: 25139411]
[33]
Drewett GP, Copaescu A, DeLuca J, Holmes NE, Trubiano JA. Asystolic cardiac arrest following liposomal amphotericin B infusion: anaphylaxis or compliment activation-related pseudoallergy? Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. 2021 Jul 29:17(1):80. doi: 10.1186/s13223-021-00582-x. Epub 2021 Jul 29
[PubMed PMID: 34325715]
[34]
Luo S, Wen H, Zhou M, Wu C, Hong D. Case report: Reversible encephalopathy associated with liposomal amphotericin B in a patient with cryptococcal meningitis. Frontiers in neurology. 2022:13():1019137. doi: 10.3389/fneur.2022.1019137. Epub 2022 Nov 9
[PubMed PMID: 36438952]
Level 3 (low-level) evidence
[35]
Palmer BF, Kelepouris E, Clegg DJ. Renal Tubular Acidosis and Management Strategies: A Narrative Review. Advances in therapy. 2021 Feb:38(2):949-968. doi: 10.1007/s12325-020-01587-5. Epub 2020 Dec 26
[PubMed PMID: 33367987]
Level 3 (low-level) evidence
[36]
Burke D, Lal R, Finkel KW, Samuels J, Foringer JR. Acute amphotericin B overdose. The Annals of pharmacotherapy. 2006 Dec:40(12):2254-9
[PubMed PMID: 17090724]